(1) Each abortion-inducing drug as defined in KRS § 311.7731 provided to a pregnant patient by a qualified physician shall be reported to the cabinet as required by KRS § 311.774.
(2) If a qualified physician provides an abortion-inducing drug as defined in KRS

Terms Used In Kentucky Statutes 311.7736

  • Federal: refers to the United States. See Kentucky Statutes 446.010
  • Treatment: when used in a criminal justice context, means targeted interventions
    that focus on criminal risk factors in order to reduce the likelihood of criminal behavior. See Kentucky Statutes 446.010

311.7731 to a pregnant woman for the purpose of inducing an abortion, and if the qualified physician knows that the woman who uses the abortion-inducing drug for the purpose of inducing an abortion experiences, during or within fifteen (15) days after the use of the abortion-inducing drug, an adverse event as defined in KRS § 311.7731, the qualified physician shall provide a written report of the adverse event within three (3) days of the event to the federal Food and Drug Administration via the MedWatch reporting system, the cabinet, and the board.
(3) Any physician, qualified physician, associated physician, or other healthcare provider who diagnoses or knowingly treats a patient, either contemporaneously to or at any time after a drug-induced abortion, for a complication or adverse event as defined in KRS § 311.7731 related to the drug-induced abortion shall make a report of the complication or adverse event to the cabinet on a report form provided by the cabinet. The report shall be completed and signed by the physician, qualified physician, or other healthcare provider who diagnosed or treated the complication or adverse event, and transmitted to the cabinet within three (3) days after the diagnosis or treatment was provided. Each report shall include at minimum the information required by KRS § 213.101.
Effective:April 14, 2022
History: Created 2022 Ky. Acts ch. 210, sec. 9, effective April 14, 2022.